

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/250541 A1

(51) International Patent Classification:

C07D 471/20 (2006.01) A61P 3/04 (2006.01)
C07D 519/00 (2006.01) A61P 19/00 (2006.01)
A61K 31/438 (2006.01) A61P 21/00 (2006.01)
A61P 1/08 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/IB2021/054970

(22) International Filing Date:

07 June 2021 (07.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/036,798 09 June 2020 (09.06.2020) US
63/167,271 29 March 2021 (29.03.2021) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BUTLER, Christopher Ryan**; 121 Spring
Lane, Canton, Massachusetts 02021 (US). **GARNSEY,
Michelle Renee**; c/o Pfizer Inc., 610 Main Street, Cam-
bridge, Massachusetts 02139 (US). **OGILVIE, Kevin
Alexander**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg.
98, Groton, Connecticut 06340 (US). **POLIVKOVA, Jana**;
c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton,
Connecticut 06340 (US). **SAMMONS, Matthew Forrest**;
c/o Pfizer Inc., 610 Main Street, Cambridge, Massachu-
setts 02139 (US). **SMITH, Aaron Christopher**; c/o Pfizer
Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecti-
cut 06340 (US). **YANG, Qingyi**; c/o Pfizer Inc., 610 Main
Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd
Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF



(57) Abstract: Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R¹, R², R³, X¹, Y¹, Y², Y³, Y⁴ and Y⁵ are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.



WO 2021/250541 A1